Cerity Partners LLC Purchases 39,345 Shares of Boston Scientific Corporation $BSX

Key Points

• Cerity Partners LLC increased its stake in Boston Scientific by 3.2% in the fourth quarter, buying 39,345 more shares and bringing its total holding to 1,265,524 shares worth about $120.7 million.
• Boston Scientific reported better-than-expected quarterly results, with EPS of $0.80 versus $0.79 expected and revenue of $5.20 billion, up 11.6% year over year. The company also issued Q2 2026 and full-year 2026 guidance above current analyst expectations.
• The company authorized a $5 billion stock buyback, allowing it to repurchase up to 6.4% of outstanding shares, while analysts maintain a Moderate Buy consensus target price of $85.92 despite several recent target cuts.

Cerity Partners LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,265,524 shares of the medical equipment provider's stock after purchasing an additional 39,345 shares during the period. Cerity Partners LLC owned about 0.09% of Boston Scientific worth $120,668,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Murphy & Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Colonial Trust Co SC raised its position in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Bangor Savings Bank raised its position in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific during the 4th quarter valued at $29,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 0.4%

Shares of NYSE:BSX opened at $48.73 on Tuesday. The business's 50-day moving average is $57.68 and its 200 day moving average is $76.17. Boston Scientific Corporation has a 1 year low of $47.17 and a 1 year high of $109.50. The firm has a market capitalization of $72.42 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the company posted $0.75 EPS. The firm's quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BSX. Barclays decreased their target price on Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 28th. Daiwa Securities Group cut Boston Scientific from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. Mizuho dropped their target price on Boston Scientific from $115.00 to $90.00 and set an "outperform" rating on the stock in a research report on Monday, April 13th. Jefferies Financial Group reduced their price target on Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Finally, Leerink Partners decreased their price objective on Boston Scientific from $87.00 to $74.00 and set an "outperform" rating for the company in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $85.92.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig purchased 3,580 shares of the company's stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the company's stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 in the last ninety days. Corporate insiders own 0.34% of the company's stock.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.